i
This Document Has Been Replaced By: Prevention and control of seasonal influenza with vaccines : recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 influenza season
Superseded
This Document Has Been Replaced By: Prevention and control of seasonal influenza with vaccines : recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 influenza season
Prevention and control of influenza : recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008
-
August 8, 2008
-
Details:
-
Personal Author:
-
Corporate Authors:United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ; Centers for Disease Control and Prevention (U.S.). Immunization Safety Office. ; National Center for Immunization and Respiratory Diseases (U.S.). Immunization Services Division. ; National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division.
-
Description:"This report updates the 2007 recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine and antiviral agents (CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2007;56[No. RR-6]). The 2008 recommendations include new and updated information. Principal updates and changes include 1) a new recommendation that annual vaccination be administered to all children aged 5--18 years, beginning in the 2008--09 influenza season, if feasible, but no later than the 2009--10 influenza season; 2) a recommendation that annual vaccination of all children aged 6 months through 4 years (59 months) continue to be a primary focus of vaccination efforts because these children are at higher risk for influenza complications compared with older children; 3) a new recommendation that either trivalent inactivated influenza vaccine or live, attenuated influenza vaccine (LAIV) be used when vaccinating healthy persons aged 2 through 49 years (the previous recommendation was to administer LAIV to person aged 5--49 years); 4) a recommendation that vaccines containing the 2008--09 trivalent vaccine virus strains A/Brisbane/59/2007 (H1N1)-like, A/Brisbane/10/2007 (H3N2)-like, and B/Florida/4/2006-like antigens be used; and, 5) new information on antiviral resistance among influenza viruses in the United States. Persons for whom vaccination is recommended are listed in boxes 1 and 2. These recommendations also include a summary of safety data for U.S. licensed influenza vaccines. This report and other information are available at CDC's influenza website (http://www.cdc.gov/flu), including any updates or supplements to these recommendations that might be required during the 2008--09 influenza season. Vaccination and health-care providers should be alert to announcements of recommendation updates and should check the CDC influenza website periodically for additional information." - p. 1
-
Content Notes:1/13/2014
JCSmith
prepared by Anthony E. Fiore, David K. Shay, Karen Broder, John K. Iskander, Timothy M. Uyeki, Gina Mootrey, Joseph S. Bresee, Nancy J. Cox.
The material in this report originated in the National Center for Immunization and Respiratory Diseases, Anne Schuchat, MD, Director; the Influenza Division, Nancy Cox, PhD, Director; the Office of the Chief Science Officer, Tanja Popovic, MD, Chief Science Officer; the Immunization Safety Office, John Iskander, MD, Acting Director, and the Immunization Services Division, Lance Rodewald, MD, Director. - p. 1
Includes bibliographical references (p. 45-59).
-
Subjects:
-
Series:
-
Pubmed ID:18685555
-
Document Type:
-
Genre:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
Related Documents
You May Also Like